Susan Reeves Whalen

Non-Disclosure

.

jhhrelaxingx560_border.jpg

Then & Now... At 20: KEG... At 65: EKG >>> Then & Now... At 20: Acid rock... At 65: Acid reflux >>> Then & Now... At 20: Trying to be like Marlon Brando... At 65: Trying NOT to be like Marlon Brando! >>> Then & Now... At 20: Seeds and stems... At 65: Roughage >>> Then & Now... At 20: Hoping for a BMW... At 65: Just bloody hoping for a BM! >>> Then & Now... At 20: Going to a new, hip joint... At 65: Receiving a new, hip joint >>> Then & Now... At 20: Rolling Stones... At 65: Kidney Stones >>> Then & Now... At 20: Passing the drivers' test... At 65: Passing the vision test >>> Then & Now... At 20: Perhaps... At 65: "Depends" >>>

Would you say it's success when clients hear from...

Parenting
Reader's Digest
Newsweek
Better Homes and Gardens
The Lisa Birnbach Show (Syndicated Radio)
ABC NEWS' 20/20
The Martha Stewart Show
Motor Trend

Client Feedback:
>>"I thought I could write my own press releases. I was wrong."
>>"You're a pro!"
>>"Before we found you our press releases went nowhere."
>>"You exceeded expectations!"

We'll get you the free publicity you deserve. We GUARANTEE it!

CONFIDENTIALITY & NONDISCLOSURE  AGREEMENT

 

This Agreement's Effective Date is the time-stamped date of Email Recipient's "Reply,"
Thereafter, this Agreement will remain in effect for 5 continuous years. 

 

The Email Recipient agrees that his/her "Reply" with the words "I accept"
followed by his/her typed name will constitute a valid digital agreement

upon hitting "Send."

 

This Agreement is between Pressure Dynamics, LLC and its future corporate assign and the EMAIL RECIPIENT to protecting confidential information disclosed by Pressure Dynamics and Email Recipient, each referred to as "Discloser".

 

"Confidential Information" (CI) is any and all information that is not readily available to the public, including but not limited to strategic plans; organization charts; acquisition and divestiture information prior to authorized release; financial reports and information prior to authorized release; research and development information; information regarding proprietary processes, inventions and prototypes; product specifications; cost and price planning data; comprehensive customer and vendor databases; personally identifiable patient healthcare information; and clinical or other scientific test results prior to authorized release; as well as other information that, under the circumstances surrounding the disclosure, in good faith, ought to be treated as proprietary or confidential. CI may be disclosed orally, in writing, by samples, by prototypes, by inspections, or by other tangible media.  CI includes all financial disclosures and CI from a third party.

 

Confidential Markings: The obligation to maintain confidentiality shall only extend to information that is identified as confidential by the Discloser.  disclosed in writing shall be clearly marked as "proprietary", "confidential', or the like. CI disclosed in any manner other than writing shall be preceded or followed by an oral or written statement that the information is CI falling within the terms of this Agreement, and such disclosure shall be followed within thirty days by a written statement describing, summarizing, or reducing to writing the CI disclosed.

 

Exceptions: The restrictions and obligations imposed by this Agreement shall not apply to information that

          is known to Recipient prior to receipt under this Agreement, as evidenced by written records;

          is disclosed without restriction to Recipient in good faith by a third party who is in lawful possession of the information and who has the right to make such disclosure;

          is or becomes public knowledge, by publication or otherwise, through no fault of Recipient;

          is independently developed by Recipient without reference to any CI received hereunder;

          is transmitted by Discloser after notification in writing by Recipient that Recipient does not wish to receive any additional CI from Discloser; and

          is required to be disclosed by law, court order, or subpoena, provided, however, that the party faced with such compulsion shall provide reasonable notice before making such disclosure to enable the other party to challenge the basis of the disclosure.

 

Use and Care of Confidential Information:  Recipient agrees that CI shall be used only to investigate a business relationship.  Recipient will treat Discloser's CI with the same care it uses to protect its own, but not less than a reasonable care under the circumstances.  Recipient may only disclose CI to employees and consultants to fulfill the purpose of this Agreement under appropriate written agreements compliant with this Agreement. Recipient shall notify Discloser immediately upon discovery of any unauthorized use or disclosure of CI or any other breach of this Agreement by Recipient, its employees and consultants, and will cooperate with Discloser in every reasonable way to help Discloser regain possession of the CI and prevent its further unauthorized use or disclosure.

 

Return of Confidential Information:  Upon request, Recipient shall promptly return to Discloser all of Discloser's CIand all copies thereof, or, at Recipient's election, shall destroy all such CI(in which instance an authorized officer of Recipient shall certify that such destruction has been completed). That portion of Discloser's CIthat consists of reviews, analyses, compilations, notes, or other documents prepared by Recipient, its employees or advisers, may be held by Recipient, provided Recipient keeps it confidential pursuant to the terms of this Agreement.  Material samples, device samples, and prototypes shall be returned rather than destroyed. Recipient may, if Recipient so elects, retain one copy of Discloser's CI in a secure location with appropriately restricted access for the limited purpose of enforcing Recipient's rights under this Agreement before a court of competent jurisdiction or pursuant to the requirements of a governmental agency or by operation of law

 

Non-Circumvention:  Recipient expressly agrees that Recipient shall not circumvent, decompile, reverse engineer, or disassemble any sample, device, prototype, hardware, software, or other material, or any portion thereof, identified as CI by Discloser.  Nothing in this Agreement grants either party any license to the other party's intellectual property

 

Miscellaneous:  This Agreement is governed by the laws of Minnesota State.  Each Discloser warrants that it has the right to make the disclosures under this Agreement, or to guarantee any future business relationship.  Information exchanged is provided "as is.”  EITHER PARTY MAKES NO OTHER WARRANTIES UNDER THIS AGREEMENT.

 

The parties will adhere to all applicable laws, regulations and rules relating to the export of technical data, and shall not export or re-export any technical data, any samples or prototypes received hereunder, or the direct product of such technical data to any proscribed country listed in such applicable laws, regulations and rules unless properly authorized. The parties further agree to comply with applicable federal and state health information confidentiality laws and regulations as to any personally identifiable patient healthcare information included as part of CI hereunder.

 

This is the entire Agreement:  There are no representations, warranties, promises or undertakings other than those stated herein.  This Agreement does not supersede any other written agreements between the parties concerning the subject matter of such other agreements.  This Agreement may not be amended except in writing signed by both parties.